Science's $400 million Series D funding round tells us something important about the current state of venture capital: despite significant headwinds, investors are still willing to place enormous bets on breakthrough technologies. The Alameda, California-based brain-computer interface company now has more than $900 million in total funding, cementing neurotech as a category worth serious capital allocation. That's remarkable given that tech stocks took a huge dive in the past few days, and that sentiment could spill over into private markets if negative pressure persists.
What's striking about this week's funding landscape is the diversity of bets being made. Yes, AI continues to attract massive checks—Model ML closed $250 million at a $1.5 billion valuation for its financial services platform. But the top 10 also includes critical metals production (General Flash, $128M), space computing infrastructure (Ramon.Space, $124M), and vehicle intelligence (Vincue, $93M). This suggests that despite macro uncertainty, venture capitalists aren't retreating into AI-only thesis. They're hedging across multiple frontiers.
The biotech surge is particularly noteworthy. Four of the top 10 deals this week went to biotech companies: Galvanize Therapeutics ($130M), Marrow Therapeutics ($120M), Seawolf Therapeutics ($100M), and even Isomorphic Labs across the Atlantic captured $5 billion—the largest financing of the week. This therapeutic focus, combined with Science's neurotech dominance at the top of the list, suggests capital is flowing toward companies solving hard biological problems, not just software optimization.
However, investors should proceed carefully. Anthropic's IPO was a headline success for the sector, but that same week saw stock market turbulence that could dampen future funding momentum. The report itself hints at this fragility: if negative sentiment persists, private markets will follow public markets down. The difference is that private markets move slower. We're likely seeing the tail end of exuberant deployment before correction sets in.
What should happen next is clear: founders and investors need to focus on sustainable unit economics rather than chasing headline valuations. Model ML's $1.5 billion valuation for a three-year-old fintech AI platform, while presumably justified internally, will face skepticism if public markets continue their dive. Science's $400 million round suggests that deep-tech companies with years of development ahead can still raise capital, but only if they're solving problems nobody else can. That's the thesis worth betting on when volatility increases.